פוסטים אחרונים

• Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma
• Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care
• Sun Pharma and LIB Therapeutics announce global licensing agreement for Lerodalcibep
• Sun Pharma Launches CTaro-Methylphenidate ER, the First and Only Bioequivalent to Concerta® with an Osmotic Delivery System
• Sun Pharma reports Q1FY27 results